- Home
- CYBN vs TCRX Comparison
CYBN vs TCRX Comparison
Compare CYBN & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- TCRX
- Stock Information
- Founded
- CYBN 2019
- TCRX 2018
- Country
- CYBN Canada
- TCRX United States
- Employees
- CYBN N/A
- TCRX N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- TCRX Health Care
- Exchange
- CYBN Nasdaq
- TCRX Nasdaq
- Market Cap
- CYBN 177.9M
- TCRX 170.1M
- IPO Year
- CYBN N/A
- TCRX 2021
- Fundamental
- Price
- CYBN $9.13
- TCRX $2.40
- Analyst Decision
- CYBN Strong Buy
- TCRX Strong Buy
- Analyst Count
- CYBN 3
- TCRX 5
- Target Price
- CYBN $138.00
- TCRX $11.40
- AVG Volume (30 Days)
- CYBN 213.0K
- TCRX 544.4K
- Earning Date
- CYBN 02-12-2025
- TCRX 03-05-2025
- Dividend Yield
- CYBN N/A
- TCRX N/A
- EPS Growth
- CYBN N/A
- TCRX N/A
- EPS
- CYBN N/A
- TCRX N/A
- Revenue
- CYBN N/A
- TCRX $9,362,000.00
- Revenue This Year
- CYBN N/A
- TCRX N/A
- Revenue Next Year
- CYBN N/A
- TCRX $5.14
- P/E Ratio
- CYBN N/A
- TCRX N/A
- Revenue Growth
- CYBN N/A
- TCRX N/A
- 52 Week Low
- CYBN $6.50
- TCRX $2.38
- 52 Week High
- CYBN $19.84
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- CYBN 45.18
- TCRX 25.27
- Support Level
- CYBN $8.83
- TCRX $2.60
- Resistance Level
- CYBN $9.41
- TCRX $2.85
- Average True Range (ATR)
- CYBN 0.59
- TCRX 0.17
- MACD
- CYBN -0.02
- TCRX 0.00
- Stochastic Oscillator
- CYBN 31.74
- TCRX 2.41
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.